Side effects of drugs annual, Год журнала: 2023, Номер unknown, С. 303 - 335
Опубликована: Янв. 1, 2023
Язык: Английский
BMC Medicine, Год журнала: 2024, Номер 22(1)
Опубликована: Март 13, 2024
Abstract Background Experiences during childhood and adolescence have enduring impacts on physical mental well-being, overall quality of life, socioeconomic status throughout one’s lifetime. This underscores the importance prioritizing health children adolescents to establish an impactful healthcare system that benefits both individuals society. It is crucial for providers policymakers examine relationship between COVID-19 adolescents, as this understanding will guide creation interventions policies long-term management virus. Methods In umbrella review (PROSPERO ID: CRD42023401106), systematic reviews were identified from Cochrane Database Systematic Reviews; EMBASE (OvidSP); MEDLINE (OvidSP) December 2019 February 2023. Pairwise single-arm meta-analyses extracted included reviews. The methodological appraisal was completed using AMSTAR-2 tool. Single-arm re-presented under six domains associated with condition. classified into five according evidence classification criteria. Rosenberg’s FSN calculated binary continuous measures. Results We 1551 301 pairwise 124 met our predefined criteria inclusion. focus meta-analytical predominantly outcomes COVID-19, encompassing study designs. However, rigor suboptimal. Based gathered meta-analyses, we constructed illustrative representation disease severity, clinical manifestations, laboratory radiological findings, treatments, 2020 2022. Additionally, discovered 17 instances strong or highly suggestive concerning long-COVID, pediatric comorbidity, vaccines, health, depression. Conclusions findings advocate implementation surveillance systems track consequences establishment multidisciplinary collaborative rehabilitation programs affected younger populations. future research endeavors, it important prioritize investigation non-physical bridge gap application in field.
Язык: Английский
Процитировано
7
Drug Safety, Год журнала: 2024, Номер 47(10), С. 991 - 1010
Опубликована: Июль 15, 2024
Pregnant persons are susceptible to significant complications following COVID-19, even death. However, worldwide COVID-19 vaccination coverage during pregnancy remains suboptimal.
Язык: Английский
Процитировано
7
Vaccine, Год журнала: 2023, Номер 41(14), С. 2382 - 2386
Опубликована: Фев. 27, 2023
Язык: Английский
Процитировано
13
Human Vaccines & Immunotherapeutics, Год журнала: 2025, Номер 21(1)
Опубликована: Фев. 11, 2025
Chikungunya virus (CHIKV), transmitted through Aedes mosquitoes, is a significant global health concern. Various vaccine platforms have been explored to combat CHIKV, including formalin inactivation, live-attenuated strains, virus-like particles (VLPs), viral vectors, and mRNA technologies. This umbrella review synthesizes evidence on the safety profiles of used in vaccines that applied other vaccines, focusing adverse events special interest (AESI) pregnant persons, children, adolescents. A comprehensive overview systematic reviews (SRs) was conducted. Results: Seven were included complemented with primary studies. Vaccines like influenza, human papillomavirus (HPV), COVID-19, which share showed no increase AESI. Moderate-to high-quality SRs supported favorable profiles. sharing generally exhibit acceptable
Язык: Английский
Процитировано
0
Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(1)
Опубликована: Янв. 2, 2023
The rapid emergence of COVID-19 variants concern (VOCs) has hindered vaccine uptake. To inform policy, we investigated the effectiveness BNT162b2 vaccination among adolescents against symptomatic and severe diseases using mostly real-world data (15 studies). We searched international databases until May 2022 used Cochrane's risk bias tools for critical appraisal. Random effects models were to examine overall (VE) across studies (general inverse-variance) effect circulating VOCs on VE (log relative ratio VE). Meta-regression assessed age time (restricted-maximum likelihood). PCR-confirmed SARS-CoV-2 was 82.7% (95%CI: 78.37–87.31%). higher (88%) than non-severe (35%) outcomes declining over improved following booster dose in omicron era [73%(95%CI:65–81%)]. Fully vaccinated are protected from by especially need care or life support.
Язык: Английский
Процитировано
9
Human Vaccines & Immunotherapeutics, Год журнала: 2023, Номер 19(1)
Опубликована: Янв. 2, 2023
We previously demonstrated the efficacy of COVID-19 vaccine candidate, SCB-2019, in adults SPECTRA phase 2/3 study. extended study to include 1278 healthy 12–17-year-old adolescents Belgium, Colombia, and Philippines who received either two doses SCB-2019 or placebo 21 days apart, assess immunogenicity as neutralizing antibodies against prototype SARS-CoV-2 variants concern, safety reactogenicity solicited unsolicited adverse events with a comparator group young (18–25 years). In participants no evidence prior infection was non-inferior that adults; respective geometric mean titers (GMT) 14 after second vaccination were 271 IU/mL (95% CI: 211–348) 144 (116–178). Most (1077, 84.3%) had serologic SAR-CoV-2 exposure at baseline; these seropositive GMTs increased from 173 (135–122) 982 (881–1094) dose. Neutralizing Delta Omicron BA also increased, most notably those exposure. well tolerated generally mild moderate, transient comparable adolescent groups except for injection site pain – reported 20% 7.3% injections. highly immunogenic adolescents, especially exposure, adults. Clinical trial registration: EudraCT 2020–004272–17; ClinicalTrials.gov NCT04672395.
Язык: Английский
Процитировано
6
Cureus, Год журнала: 2024, Номер unknown
Опубликована: Фев. 4, 2024
Introduction The COVID-19 pandemic has presented an unprecedented global health issue. World Health Organization estimates 773 million confirmed cases and 7 deaths. Vaccination continues to be the most effective way prevent demonstrated safety efficacy in all age groups. Though a lot of studies have looked at vaccination acceptance hesitancy adults, there is scarce research addressing adolescent readiness. infection this group may result lost school days, community transmission, loss productivity for parents. Aim This study aims determine rates factors influencing its adolescents setting. Methods A voluntary survey was conducted local high May 2023. Information collected about demographics educational background parents/guardians. assessed COVID vaccine rate, reasons or refusal, number doses boosters received, prior history infection, source information on vaccine, flu by students, whether they would willing take booster. Results Four hundred participants, ranging from 13 19, were surveyed. rate boys comparable that girls. 72% received least one 66% considered completely vaccinated. Of those vaccinated, 80% had undergone further updated booster vaccinations. Adolescents whose parents/guardians college graduates higher than not. Caucasians Asians compared African Americans mixed races. not statistically different with versus no infection. Flu associated rates. Lack trust important reason hesitancy, along questions efficacy, concerns side effects, parent/guardian decisions, religious reasons. Protecting oneself, family/friends, major vaccine. Parents/guardians, physicians, peers, television, social media, flyers, schools primary sources relied vaccination. Conclusion Lower education attainment among parents/guardians, Americans, races lower fear effects frequently cited hesitancy. Parent/guardian influence other significant Understanding will allow us address barriers vaccinations appropriate group. Educating schools, involving state departments increase awareness educating parents guardians teenagers can help These interventions also positively affect prepare any future pandemics.
Язык: Английский
Процитировано
0
medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2023, Номер unknown
Опубликована: Фев. 26, 2023
ABSTRACT We previously demonstrated efficacy of the COVID-19 vaccine candidate, SCB-2019, in adults SPECTRA phase 2/3 study. extended study to include 1278 healthy 12–17-year-old adolescents Belgium, Colombia and Philippines who received either two doses SCB-2019 or placebo 21 days apart, assess immunogenicity as neutralizing antibodies against prototype SARS-CoV-2 variants concern, safety reactogenicity solicited unsolicited adverse events with a comparator group young (18–25 years). In participants no evidence prior infection was non-inferior that adults; respective geometric mean titers (GMT) 14 after second vaccination were 271 IU/mL (95% CI: 211–348) 144 (116–178). Most (1077, 84.3%) had serologic SAR-CoV-2 exposure at baseline; these seropositive GMTs increased from 173 (135–122) 982 (881–1094) dose. Neutralizing Delta Omicron BA also increased, most notably those exposure. well tolerated generally mild moderate, transient comparable adolescent groups except for injection site pain – reported 20% 7.3% injections. highly immunogenic adolescents, especially exposure, adults. Clinical trial registration EudraCT 2020-004272-17; ClinicalTrials.gov NCT04672395 .
Язык: Английский
Процитировано
0
Side effects of drugs annual, Год журнала: 2023, Номер unknown, С. 303 - 335
Опубликована: Янв. 1, 2023
Язык: Английский
Процитировано
0